Samsung Bioepis Reports Results of Post-Hoc Analysis from P-III Study of Byooviz (biosimilar, ranibizumab) for the Treatment of nAMD

September 10, 2021 Auto Bot Biosimilar, Biosimilars, Clinical Trials, P-III, ranibizumab, Samsung Bioepis, Study 0

Shots:

  • The P-III study evaluates Byooviz (0.5 mg, IVT) vs ranibizumab in 634 patients with nAMD. The results will be presented at EURETINA 2021
  • The 1EPs are changed from baseline in BCVA @8wks. and change in CST @4wks. with both EPs, followed by 52wks. The post-hoc analysis showed that the baseline age, BCVA, CST, and total lesion size were identified to be associated with the visual acuity & anatomical outcomes
  • In subgroup analysis, similar visual outcomes of 2 products in change from baseline in BCVA in multiple subgroups were observed & support an equivalent clinical efficacy. Byooviz is an effective & valuable treatment option for nAMD patients globally

Click here to read full press release/ article | Ref: | Image: PharmaLive

The post Samsung Bioepis Reports Results of Post-Hoc Analysis from P-III Study of Byooviz (biosimilar, ranibizumab) for the Treatment of nAMD first appeared on PharmaShots.